Pacing and Ablation for Patients with Atrial Fibrillation
Official title: Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation
Run by Seoul National University Hospital · NCT06699342 · Data updated 2026-11-12
This study is testing whether a combination of a special pacemaker and a procedure to block heart signals can help people with tough-to-treat atrial fibrillation feel better compared to just using medications.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul, Jongno-gu) |
| Status | Recruiting |
| Started | January 27, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT06699342 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 65 and older with permanent atrial fibrillation who are refractory or intolerant to standard drug therapies.
✕Probably not a fit
Patients with asymptomatic atrial fibrillation or those with a life expectancy of less than 12 months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial compares the outcomes of left bundle branch area pacing combined with atrioventricular node ablation against optimized pharmacologic treatment in patients suffering from symptomatic atrial fibrillation who are refractory or intolerant to drug therapy or catheter ablation. It is a multicenter, randomized, open-label trial involving 50 patients, with a 1:1 randomization. The study will assess primary outcomes over 6 months and secondary outcomes over 24 months, focusing on the effectiveness of the interventions. Procedures include pacemaker implantation and ablation techniques tailored to individual patient needs.
Why it matters
Potential benefit: If successful, this approach could provide a new treatment option for patients with difficult-to-manage atrial fibrillation.
How similar studies have gone: While this approach is innovative, similar studies have shown promise in managing atrial fibrillation with pacing and ablation techniques.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion: Patients who meet all of the following inclusion criteria 1)-6). 1. Permanent atrial fibrillation 2. Age ≥ 65 years 3. Refractory or intolerant to antiarrhythmic drugs, rate control medications, or catheter ablation 4. New York Heart Association (NYHA) functional class II- IV 5. LVEF \> 40% (within the past 3 months) 6. Patients with at least one of the following: 1. HF hospitalization (defined as HF as the major reason for hospitalization or treatment for HF lasting ≥12 hours and including treatment with intravenous (IV) diuretics at a healthcare facility) within 12 months 2. Elevated NT-proBNP (\>900 pg/ml) in the 30 days prior to enrollment Exclusion: Patients who meet at least one of the following exclusion criteria 1)-11). 1. Asymptomatic atrial fibrillation 2. Life expectancy to \< 12 months. 3. Primary moderate to severe valvular disease (except for functional mitral valve regurgitation or tricuspid valve regurgitation) 4. Mechanical tricuspid valve replacement 5. Severe chronic kidney disease (estimated Glomerular Filtration Rate ≤ 15 ml/1,73 m2 or receiving renal replacement treatment including hemodialysis or peritoneal dialysis) 6. Obstructive hypertrophic cardiomyopathy 7. Infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others) 8. Acute coronary syndrome or coronary revascularization (CABG or PCI) \<3 months 9. Severe primary pulmonary disease such as cor pulmonale, irreversible lung disease requiring inhalers, oxygen supplementation 10. Pacemaker/ICD/CRT treatment ongoing, or current pacemaker indication 11. Simultaneous participation in a different randomized clinical trial
Where it's running
-
Seoul National University Hospital
Seoul, Jongno-gu, South Korea Recruiting
Study contacts
- Study coordinator: Eue-keun Choi, M.D. Ph.D
- Email: choiek417@gmail.com
- Phone: 82-2-2072-0688
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation
This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.
-
Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation
This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.
-
Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF
This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes
This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.
-
AI-based cardiac analysis using 12-lead and 1-lead ECG
A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.